Jenscare Scientific has received CE mark approval under the EU Medical Device Regulation (MDR) for its LuX-Valve Plus transvenous tricuspid valve replacement (TTVR) system, expanding treatment options for patients with severe tricuspid regurgitation.
The second-generation device is designed to replace the native tricuspid valve through a transvascular approach, avoiding open-heart surgery. According to the company, the system offers multi-angle adjustability and steerability to support more precise valve positioning while reducing procedure time, incision size, and tissue trauma.
Related: Medicaroid receives CE mark for Hinotori surgical robot
The approval strengthens Jenscare’s position in the growing TTVR market, where companies are developing minimally invasive alternatives for treating tricuspid valve disease.
The company said:
“This achievement reflects our unwavering commitment to advancing innovation in the field of structural heart disease and expanding therapeutic options for patients suffering from tricuspid regurgitation.”
